Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act.
作者信息
Johnson Micah, Nayak Rahul K, Gilstrap Lauren, Dusetzina Stacie B
机构信息
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
出版信息
JAMA Cardiol. 2023 Mar 1;8(3):299-301. doi: 10.1001/jamacardio.2022.5033.
Abstract
摘要
相似文献
1
Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act.医疗保险D部分和《降低通胀法案》下心力衰竭指南指导药物治疗的自付费用估算
JAMA Cardiol. 2023 Mar 1;8(3):299-301. doi: 10.1001/jamacardio.2022.5033.
2
The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease.《降低通胀法案》与心血管疾病 Medicare 受益人的自付药物费用。
J Am Coll Cardiol. 2023 May 30;81(21):2103-2111. doi: 10.1016/j.jacc.2023.03.414.
3
Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.评估 2009 年和 2019 年治疗患有多种慢性病的老年人的指南推荐药物的假设自付费用。
JAMA Intern Med. 2022 Feb 1;182(2):185-195. doi: 10.1001/jamainternmed.2021.7457.
4
Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.估算《降低通胀法案》对患有晚期前列腺癌的 Medicare 受益人的自付费用的影响。
Urol Pract. 2023 Sep;10(5):476-483. doi: 10.1097/UPJ.0000000000000425. Epub 2023 Jul 3.
5
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure.医疗保险覆盖范围和心力衰竭四联药物治疗的自付费用。
J Am Coll Cardiol. 2022 Jun 28;79(25):2516-2525. doi: 10.1016/j.jacc.2022.04.031.
6
Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction.医疗保险按服务收费受益人与射血分数降低的心力衰竭患者的 Part D 覆盖药物的自付费用。
Am Heart J. 2022 Apr;246:74-81. doi: 10.1016/j.ahj.2021.10.189. Epub 2021 Nov 11.
7
Prescription drug spending and hospital use among Medicare beneficiaries with heart failure.医疗保险受益人心力衰竭患者的处方药支出和医院使用情况。
Res Social Adm Pharm. 2020 Oct;16(10):1452-1458. doi: 10.1016/j.sapharm.2019.12.019. Epub 2019 Dec 26.
8
Dermatology medications with the highest cost burden on Medicare Part D: Potential implications of the Inflation Reduction Act.医疗保险计划 D 部分费用负担最重的皮肤科药物：《降低通胀法案》的潜在影响。
J Am Acad Dermatol. 2024 Aug;91(2):379-381. doi: 10.1016/j.jaad.2024.04.030. Epub 2024 Apr 23.
9
Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.医疗保险部分 D 下沙库巴曲缬沙坦的国家覆盖范围和自付费用评估。
JAMA Cardiol. 2019 Aug 1;4(8):828-830. doi: 10.1001/jamacardio.2019.2223.
10
The economic impact of Medicare Part D on congestive heart failure.医疗保险处方药部分对充血性心力衰竭的经济影响。
Am J Manag Care. 2013 May;19(6 Suppl):s97-100.
引用本文的文献
1
Using the 5Ms Framework to Advance Aging-Responsive Care for Heart Failure with Reduced Ejection Fraction.运用5M框架推进对射血分数降低的心力衰竭的老龄响应性护理。
Clin Interv Aging. 2025 Mar 20;20:325-333. doi: 10.2147/CIA.S493243. eCollection 2025.
2
2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.《2025年心脏病和中风统计数据：美国心脏协会关于美国和全球数据的报告》
Circulation. 2025 Feb 25;151(8):e41-e660. doi: 10.1161/CIR.0000000000001303. Epub 2025 Jan 27.
3
Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF).将自付费用纳入射血分数降低的心力衰竭共同决策：一项阶梯楔形试验（POCKET-COST-HF）
Circ Cardiovasc Qual Outcomes. 2025 Jan;18(1):e011273. doi: 10.1161/CIRCOUTCOMES.124.011273. Epub 2024 Dec 3.
4
Guideline-directed medical therapy implementation during hospitalization for cardiogenic shock.在心源性休克住院期间实施指南指导的药物治疗。
ESC Heart Fail. 2025 Feb;12(1):60-70. doi: 10.1002/ehf2.14863. Epub 2024 Sep 26.
5
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.2024 年心脏病与中风统计数据：美国心脏协会发布的美国和全球数据报告。
Circulation. 2024 Feb 20;149(8):e347-e913. doi: 10.1161/CIR.0000000000001209. Epub 2024 Jan 24.
Zotero 插件